COMMISSIONED EQUITY RESEARCH
CRUNCHFISH: Rights issue to stay the course on extended timeline
Read More Read Less
COMMISSIONED EQUITY RESEARCH
GRANGEX: Emerging as Europe’s top DR concentrate developer
Read More Read Less
COMMISSIONED EQUITY RESEARCH
GRANGEX: Updated DFS confirming viability to produce high-grade iron ore at Dannemora
Read More Read Less
COMMISSIONED EQUITY RESEARCH
PROLIGHT: Pre-validation readout in Q4 sets stage for multicenter trial in 2025
Read More Read Less
COMMISSIONED EQUITY RESEARCH
Nanexa AB: NEX-22 Progress, Revaluation and Financing
Read More Read Less
COMMISSIONED EQUITY RESEARCH
CRUNCHFISH: Three avenues to address the strained financing
Read More Read Less
COMMISSIONED EQUITY RESEARCH
Prolight Diagnostics: SEK 17m UK grant a welcome external validation
Read More Read Less
COMMISSIONED EQUITY RESEARCH
NANEXA: Insights from CMD underscore near- to mid-term opportunities with significant potential
Read More Read Less
COMMISSIONED EQUITY RESEARCH
GRANGEX: Striking renegotiation of Sydvaranger acquisition setting GRANGEX up for an eventful 2024
Read More Read Less
COMMISSIONED EQUITY RESEARCH
CRUNCHFISH: Broadening of scope to all offline credentials
Read More Read Less
COMMISSIONED EQUITY RESEARCH
PROLIGHT: Important milestone amidst mixed news flow
Read More Read Less
COMMISSIONED EQUITY RESEARCH
CRUNCHFISH: Major TAM expansion with broadening to secure and scalable mobile card payments
Read More Read Less
COMMISSIONED EQUITY RESEARCH
PROLIGHT: PoC troponin testing ready for next step
Read More Read Less
COMMISSIONED EQUITY RESEARCH
NANEXA: Focus on dual GLP-1 opportunities and the partner projects
Read More Read Less
COMMISSIONED EQUITY RESEARCH
GRANGEX: Starting to fuel up: GRANGEX set for busy agenda in 2024
Read More Read Less